12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vorapaxar: Phase III data

Top-line data from the double-blind, international Phase III TRA-2P trial in 26,449 patients showed that vorapaxar plus standard of care (SOC) met the composite primary endpoint of significantly reducing the incidence of cardiovascular death, MI, stroke or urgent coronary revascularization vs. placebo plus SOC. Merck did say the vorapaxar arm led to a significant increase in bleeding, including intracranial hemorrhage, vs. the placebo arm, but that the risk of intracranial hemorrhage was lower in patients without a history of stroke. The trial enrolled patients with a prior heart attack, ischemic stroke or peripheral arterial disease (PAD) to receive placebo or once-daily 2.5 mg vorapaxar in combination with SOC...

Read the full 516 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >